Yes, Cosentyx (secukinumab) is FDA-approved for active ankylosing spondylitis in adults.[1][2] It targets interleukin-17A to reduce inflammation and symptoms like back pain and stiffness. Clinical trials showed significant improvement in ASAS20 response rates compared to placebo.[2]

The standard dose is 150 mg subcutaneous injection every 4 weeks after initial loading doses.[1]

Sources
[1]: FDA Label for Cosentyx
[2]: Novartis Cosentyx Prescribing Information